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Background: Bronchiectasis–chronic obstructive pulmonary disease (COPD) overlap presents 
a possible clinical phenotype of COPD, but it is unclear why it develops in a subset of patients. 
We hypothesized that sensitization to Aspergillus fumigatus (A fum) is associated with bron-
chiectasis in COPD and occurs more frequently in vitamin D-deficient patients.
Methods: This observational study investigated sensitization to A fum in an outpatient clinical 
cohort of 300 COPD patients and 50 (ex-) smoking controls. Total IgE, A fum-specific IgE against 
the crude extract and against the recombinant antigens and A fum IgG were measured using 
ImmunoCAP fluoroenzyme immunoassay. Vitamin D was measured by radioimmunoassay, and 
computed tomography images of the lungs were scored using the modified Reiff score.
Results: Sensitization to A fum occurred in 18% of COPD patients compared to 4% of controls 
(P=0.0110). In all, 31 COPD patients (10%) were sensitized to the crude extract and 24 patients 
(8%) had only IgE against recombinant antigens. A fum IgG levels were significantly higher in 
the COPD group (P=0.0473). Within COPD, A fum-sensitized patients were more often male 
(P=0.0293) and more often had bronchiectasis (P=0.0297). Pseudomonas aeruginosa and 
Serratia marcescens were more prevalent in historical sputum samples of A fum-sensitized COPD 
patients compared to A fum-non-sensitized COPD patients (P=0.0436). Vitamin D levels were 
comparable (P=0.2057). Multivariate analysis demonstrated that sensitization to recombinant 
f1 or f3 had a 2.8-fold increased risk for bronchiectasis (P=0.0030).
Conclusion: These results highlight a potential role for sensitization to A fum in COPD-related 
bronchiectasis.
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Background
Chronic obstructive pulmonary disease (COPD) is highly prevalent and a leading 
cause of morbidity and mortality worldwide. Both social and economic burden 
continue to rise.1 It has become widely accepted that the degree of airflow limita-
tion is insufficient to estimate the severity and heterogeneity of COPD. Symptoms, 
exacerbations and comorbidities are well-established determinants.2 Furthermore, 
there is growing interest in phenotyping the disease not only based on clinical char-
acteristics but also on genetic, molecular and cellular parameters.3,4 By differentiat-
ing phenotypes, a more personalized and effective therapy might be achieved for 
subgroups of patients.
Jamieson et al5 demonstrated that COPD patients with allergic sensitization expe-
rience more symptoms and exacerbations. Although hypersensitivity to Aspergillus 
fumigatus (A fum) was not measured here, two other studies have reported on the 
higher prevalence of A fum sensitization in COPD and its association with worse 
lung function.6,7 Sensitization is defined by the presence of allergen-specific IgE, 
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which is routinely measured by skin prick test or in vitro 
immunoassay. In general, a crude extract of A fum is used, 
although purified or recombinant antigens of A fum are more 
specific.8 Different studies suggest a role for these recom-
binant antigens in distinguishing patients with and without 
allergic bronchopulmonary aspergillosis (ABPA) in cystic 
fibrosis (CF) and asthma.9,10 Whether A fum recombinant 
antigens are also of interest in other lung diseases such as 
COPD is not known.
COPD–bronchiectasis overlap syndrome is a potential 
clinical phenotype.11 Prevalence varies greatly depending 
on the definition and methodology. Recent literature shows 
that bronchiectasis is clinically important12–14 and composes 
an independent risk factor for mortality in COPD.14–16 
Moreover, diagnosis of bronchiectasis in COPD has an 
impact on therapeutic considerations such as the safety of 
inhaled corticosteroids, the need for inhaled antibiotics or 
maintenance therapy with azithromycin and the antimicrobial 
management of exacerbations. At present, the pathogenesis 
of non-CF bronchiectasis is explained by a vicious circle in 
which inflammation causes structural damage and impaired 
mucus clearance, which in turn promotes bacterial coloniza-
tion and infection, again resulting in more inflammation.17 
The triggers for the development of bronchiectasis in 
COPD are not known. Given the multiple links between 
Aspergillus species and bronchiectasis,18 we hypothesize 
that A fum may play an important role in the development 
of COPD-related bronchiectasis. As A fum sensitization and 
bronchiectasis may have a common link through suppression 
of the vitamin D signaling pathway,19–21 we also speculate 
that vitamin D deficiency, which is frequently observed in 
COPD and bronchiectasis,22,23 may also contribute to A fum 
sensitization.
We performed an observational study in a COPD cohort 
and a smoking control group recruited from the outpatient 
clinic of the University Hospitals of Leuven. We explored 
if A fum sensitization was more prevalent in COPD patients 
versus controls by measuring IgE against the crude A fum 
extract and five commercially available A fum recom-
binant antigens. We hypothesized that A fum-sensitized 
COPD patients have different clinical characteristics, lower 
vitamin D serum levels and more bronchiectasis compared 
to COPD patients without A fum sensitization.
Methods
study design and subjects
In this observational study, subjects were retrospectively 
selected from the Leuven COPD cohort, a DNA, plasma 
and serum bank of a clinical-based COPD population and 
controls (NCT00858520). Inclusion criteria were an age 
of $50 years and a smoking history of $10 pack-years. 
A recent diagnosis of cancer, respiratory disorders other than 
COPD, major thoracic surgery and solid organ transplanta-
tion were exclusion criteria. Medical history, clinical param-
eters, therapy and the modified Medical Research Council 
(mMRC) breathlessness scale24 were surveyed. Exacerbations 
were defined as acute events with worsening of respiratory 
symptoms that were beyond normal day-to-day variations and 
led to a change in medication.2 The number of exacerbations 
in the year prior to inclusion was recorded. The combined 
assessment as proposed by the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) was used to stage the 
severity of COPD: breathlessness (mMRC) and exacerba-
tion history were used to subdivide COPD patients into four 
stages; A, B, C and D.2 The study was approved by the local 
ethics committee (Medical Ethical Board of the University 
Hospitals Leuven, Belgium – ML11081), and all patients 
provided written informed consent. We selected 300 patients 
with an established diagnosis of COPD based on a post-
bronchodilator forced expiratory volume in 1 second (FEV
1
)/
forced vital capacity (FVC) ratio ,0.7, who were included 
between October 2007 and September 2013. Selection of our 
study patients was based on Caucasian race, the availability 
of complete pulmonary function data and 1 mm thin-sliced 
computed tomography (CT) imaging of the thorax. The 
control group consisted of 50 (ex-) smokers with a post-
bronchodilator FEV
1
/FVC ratio .0.7, who were enrolled in 
a lung cancer screening trial (NELSON, ISRCTN63545820) 
between October 2007 and October 2009.25
Pulmonary function
Post-bronchodilator spirometry was measured at the time 
of recruitment using a standardized equipment (Sensor-
medics Whole Body Plethysmograph; Viasys Healthcare, 
Vilvoorde, Belgium), according to the American Thoracic 
Society/European Respiratory Society guidelines.26 Diffusion 
capacity was measured by the single-breath carbon monoxide 
gas transfer method.27 Results are reported as percentages 
predicted of reference values. COPD was diagnosed based 
on a post-bronchodilator FEV
1
/FVC ratio of ,0.7, and the 
post-bronchodilator FEV
1
 was used to classify patients 
according to the GOLD classification.2
CT images
All subjects had a CT of the thorax within 1 year of enroll-
ment. CT scans were taken for a variety of indications, which 
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resulted in the use of different protocols in the COPD group. 
Nevertheless, only patients with slices of 1 mm were included 
in this study. Subjects in the control group were all scanned 
according to the same protocol as described before.25 Airway 
dilatation was determined based on Naidich’s descriptions: 
bronchoarterial ratio .1, lack of tapering, presence of bron-
chus within 1 cm of costal pleura or abutting the mediastinal 
pleura.28 All scans were blinded to the other data and scored 
for bronchiectasis using the modified Reiff score. This score 
ranges from 0 to 18 by assessing the number of involved lobes 
(the lingula considered separately) and the degree of bron-
chodilation (1= tubular, 2= varicose and 3= cystic).29 A score 
of $2 was considered clinically relevant because minor bron-
chial dilatation is also described in healthy individuals.30
Blood analysis
Plasma was collected in cryotubes and stored at -80°C. 
Total IgE, IgE against A fum extract and against A fum 
recombinant antigens f1–f4 and f6 and A fum IgG were 
determined by ImmunoCAP fluoroenzyme immunoassay 
using an ImmunoCAP 1000 instrument (Phadia AB, Uppsala, 
Sweden). A cutoff of 114 kU/L was used for total IgE,31 and 
specific IgE values .0.35 kU/L were considered positive. 
We present the specific IgE results as proportions rather 
than absolute values due to the detection limit and the clini-
cal relevance. 25-Hydroxy-vitamin D was measured using 
radioimmunoassay (RIA; DiaSorin, Brussels, Belgium) with 
results expressed in micrograms per liter.
sputum
In the COPD group, the presence of potential pathogenic 
microorganisms (PPM) in historical sputum cultures was 
assessed from laboratory reports. All sputum cultures that 
were performed in our hospital since 2002 were evaluated. 
These sputum samples were mainly collected during bron-
chitis or exacerbation episodes. We registered if they ever 
had PPM cultured, and if so, which different species were 
found. All cultures were performed according to the standard 
protocol of our hospital. In brief, 10 µL of sputum sample was 
inoculated on four different agars: blood agar, Haemophilus-
specific agar, mannitol salt agar and MacConkey agar. These 
were cultured for 2 days.
statistical analysis
Statistical analysis was performed with GraphPad Prism 4 
(GraphPad Software, Inc., La Jolla, CA, USA) and SAS 
software version 9.4 (SAS Institute Inc., Cary, NC, USA). 
Normality was tested by the Shapiro–Wilk test; none of the 
continuous variables were normally distributed. Univariate 
comparisons between groups were performed by Wilcoxon 
rank-sum test and presented as median ± interquartile range 
(IQR). Proportions of discrete variables were compared 
with χ2 test and presented as absolute numbers and percent-
ages. We built a multivariate logistic regression model to 
study the association between sensitization to A fum recom-
binant f1 (rAsp f1) or A fum recombinant f3 (rAsp f3) and 
bronchiectasis in COPD. After performing bivariable logistic 
regression models with modified Reiff score $2 as exposure, 
potential confounders of the association between sensitization 
and the presence of bronchiectasis were included in the final 
model if they 1) changed the estimate of the multivariable 
model $10% or 2) the variable was significantly associated 
with the presence of bronchiectasis. P-values ,0.05 were 
considered significant in all analyses.
Results
study group characteristics
A total of 350 subjects were included in this study: 
300 patients with COPD and 50 (ex-) smoking controls. 
There was no difference in gender. Patients in the COPD 
group were older, smoked more and had a lower mean body 
mass index (BMI) than controls (Table 1). The COPD group 
had a median FEV
1
 of 43% predicted and a median diffusion 
capacity of 46% predicted. The majority of COPD patients 
were staged in GOLD classes 2 and 3 or groups B and D.32 
Table 1 study group characteristics
Characteristic Control COPD P-values
Patients (n) 50 300
Men (%) 37 (74.0) 215 (71.7) 0.7337
age, years 62 (58–68) 67 (61–74) 0.0002
Pack-years 35.5 (26.8–46.8) 48.9 (34.0–64.1) 0.0001
Current smokers (%) 26 (52) 125 (42) 0.1781
BMI, kg/m2 27.3 (23.9–29.4) 24.1 (20.7–27.5) 0.0004
FeV1, l 2.9 (2.4–3.4) 1.2 (0.9–1.6) na
FeV1, % pred 104 (92–111) 43 (34–58) na
Dl,co, mmol/min/Kpa 7.5 (6.1–8.9) 3.8 (3.0–5.0) na
Dl,co, % pred 83 (78–94) 46 (36–58) na
gOlD 1/2/3/4, % na 5.7/32.0/45.7/16.7 na
gOlD assessment 
a/B/C/D, %
na 4.0/21.3/5.3/69.3 na
Vitamin D, µg/l 28.5 (21.2–35.5) 17.3 (12.4–23.1)a ,0.0001
Modified Reiff 
score $2 (%)
5 (10) 99 (33) 0.0010
Notes: Data are presented as n, n (%), median (interquartile range) or %. aBased 
on 240 COPD patients after exclusion of subjects taking vitamin D supplements. 
P-values ,0.05 are shown in bold.
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body mass 
index; FeV1, forced expiratory volume in 1 second; % pred, percentage predicted; 
Dl,co, diffusion capacity of the lung for carbon monoxide; gOlD, global Initiative 
for Chronic Obstructive lung Disease; na, not applicable.
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In vitamin D non-supplemented COPD patients (n=240), a 
significantly lower median vitamin D level was observed 
compared to the control group (17.3 versus 28.5 µg/L, 
P,0.0001). The proportion of subjects with bronchiectasis 
was higher in the COPD group compared to controls (33% 
versus 10%, P=0.0010). More detailed information about the 
study groups is given in Table 1.
Total Ige and A fum-specific antibodies
Total IgE, A fum-specific IgE against the crude extract and 
the recombinants and A fum-specific IgG were measured to 
determine antibody production against A fum. Details of these 
results are given in Table 2. There was a tendency to higher 
total IgE levels and more prevalent IgE against A fum extract 
in COPD patients compared to controls (Figure 1A and B). 
If recombinant antigens were considered, significantly 
more COPD patients than controls had IgE against rAsp 
f1 (12% versus 2%, P=0.0332; Figure 1B). Sensitization 
to A fum extract and rAsp f1 occurred in different patients: 
out of 50 patients sensitized to one of these two allergens, 
only 17 patients developed IgE antibodies .0.35 kU/L 
against both A fum extract and rAsp f1 (Table 3). IgEs 
against A fum recombinant f2 (rAsp f2), A fum recombinant 
f4 (rAsp f4) and A fum recombinant f6 (rAsp f6) were only 
rarely present in both groups, while there was no significant 
difference in IgE against rAsp f3 (Figure 1B). The difference 
in sensitization to at least one of the tested allergens was sta-
tistically significant: 55 (18.3%) COPD patients versus two 
(4%) controls, P=0.0110 (Figure 1B). Furthermore, COPD 
patients had a higher median level of A fum IgG (31 versus 
20.7 mg/L, P=0.0473; Figure 1C).
Differences between sensitized and non-
sensitized COPD patients
Clinical and demographic characteristics were compared 
between 55 A fum-sensitized COPD patients and 245 
A fum-non-sensitized COPD patients. In the sensitized 
group, the proportion of men was significantly higher (83.6% 
versus 69%, P=0.0293). There was no difference in age, 
Table 2 Total Ige and A fum-specific antibodies
Variables Control COPD P-values
Patients (n) 50 300
Total Ige, kU/l 42.5 (16.5–105.5) 52.0 (17.0–198.5) 0.3068
Total Ige .114, 
kU/l (%)
11 (22) 103 (34.3) 0.0849
A fum extract Ige (%) 1 (2) 31 (10.3) 0.0584
rasp f1 Ige (%) 1 (2) 36 (12) 0.0332
rasp f2 Ige (%) 1 (2) 7 (2) 0.8839
rasp f3 Ige (%) 1 (2) 20 (6.7) 0.1983
rasp f4 Ige (%) 0 (0) 3 (1) 0.4776
rasp f6 Ige (%) 0 (0) 4 (1.3) 0.4115
sensitized in total (%)a 2 (4) 55 (18.3) 0.0110
A fum Igg, mg/l 20.7 (9.6–42.8) 31.0 (15.9–48.5) 0.0473
Notes: Data are presented as n, median (interquartile range) or n (%). P-values ,0.05 
are shown in bold. asensitization to at least one of the A fum allergens including the 
extract.
Abbreviations: COPD, chronic obstructive pulmonary disease; A fum, Aspergillus 
fumigatus; rasp f1, A fum recombinant f1; rasp f2, A fum recombinant f2; rasp f3, A 
fum recombinant f3; rasp f4, A fum recombinant f4; rasp f6, A fum recombinant f6.
Figure 1 Total Ige and A fum-specific antibodies in patients with COPD versus controls.
Notes: Antibody levels were measured in plasma by ImmunoCAP fluoroenzyme immunoassay using an ImmunoCAP 1000 instrument (Phadia AB, Uppsala, Sweden). 
(A) Median values of total IgE. No significant difference between controls and COPD, P=0.3068. (B) Proportions of subjects with Ige against different A fum allergens: extract 
of A fum, A fum recombinant f1 (rasp f1), A fum recombinant f2 (rasp f2), A fum recombinant f3 (rasp f3), A fum recombinant f4 (rasp f4) and A fum recombinant f6 (rasp f6). 
Total shows the proportion of participants sensitized against at least one of the tested allergens (*P,0.05). (C) Median values of A fum-specific IgG. Difference between 
COPD and control was significant (**P=0.0473).
Abbreviations: COPD, chronic obstructive pulmonary disease; A fum, Aspergillus fumigatus; rasp f1, A fum recombinant f1; rasp f2, A fum recombinant f2; rasp f3, A fum 
recombinant f3; rasp f4, A fum recombinant f4; rasp f6, A fum recombinant f6.





 U$VSI U$VSI U$VSI U$VSI U$VSI 7RWDO$IXP
3DU
WLFLS
DQWV
 &RQWURO&23'









 &RQWURO &23'
$IX
P,J
*P
J/






 &RQWURO &23'
7RWD
O,J(
N8
/
$ % &
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2633
Aspergillus fumigatus sensitization and bronchiectasis in COPD
BMI, smoking history and use of inhaled corticosteroids. 
Furthermore, lung functional variables and GOLD stages 
were not different and sensitized patients did not experience 
more exacerbations compared to non-sensitized patients. 
Vitamin D levels were comparable in the sensitized versus 
non-sensitized COPD patients (16.2 versus 18.1 ng/mL, 
P=0.2057). However, median values of specific A fum 
IgG were higher in A fum-sensitized patients (43.2 versus 
27.7 mg/L, P,0.0001), who also had significantly more 
bronchiectasis compared to non-sensitized patients (45.5% 
versus 30.2%, P=0.0297). Data are presented in Table 4.
Interestingly, bronchiectasis was only detected in pati-
ents with sensitization to recombinants. None of the nine 
patients who were only sensitized to the crude extract – and 
therefore not to any of the recombinant allergens – had 
bronchiectasis. In contrast, patients with IgE against rAsp 
f1, and especially against rAsp f3, had significantly more 
bronchiectasis than patients without sensitization to these 
allergens (Table 5).
Results of sputum cultures were available in 197 patients. 
The median number of sputum samples per patient was not 
different between groups (4 [IQR 2–6] in sensitized patients 
and 3 [IQR 1–5] in non-sensitized patients, P=0.0692). PPM 
were significantly more prevalent in A fum-sensitized versus 
A fum-non-sensitized patients (76.9% versus 59.5%, 
P=0.0436; Table 4). Sputum cultures showed no difference 
in the presence of typical COPD pathogens like Streptococcus 
pneumonia, Haemophilus influenza and Moraxella 
catarrhalis. In contrast, Pseudomonas aeruginosa and 
Serratia marcescens were more common in sputum cultures of 
A fum-sensitized patients (Figure 2).
Multivariate analysis with logistic regression showed 
a significant association between bronchiectasis, sensitiza-
tion to rAsp f1 or rAsp f3 (P=0.0030) and age in COPD, 
independent of gender, BMI, diffusion capacity and pres-
ence of $2 exacerbations/year (Table 6). This significant 
association between rAsp f1 or rAsp f3 sensitization and 
bronchiectasis was confirmed with the same model in the sub-
group of patients with sputum samples (n=197, P=0.0021), 
additionally corrected for the presence of PPM (Table 6).
Table 4 A fum-sensitized COPD patients versus A fum-non-sensitized COPD patients
Characteristic COPD patients  
non-sensitized to A fum
COPD patients  
sensitized to A fum
P-values
Patients (%) 245 (81.7) 55 (18.3)
Men (%) 169 (69.0) 46 (83.6) 0.0293
age, years 67 (61–74) 68 (64–74) 0.2767
BMI, kg/m2 24.4 (20.9–27.7) 23.3 (19.7–26.9) 0.0785
Pack-years 48.0 (33.5–63.8) 52.5 (35.3–66.0) 0.3518
Current smoking (%) 99 (40.6) 26 (47.3) 0.3629
ICs (%) 197 (80.4) 49 (89.1) 0.1299
FeV1, l 1.18 (0.86–3.93) 1.70 (0.83–2.86) 0.7632
FeV1, % pred 43 (34–58) 41 (33–56) 0.4461
Dl,co, mmol/min/Kpa 3.9 (3.0–9.6) 3.6 (2.7–7.7) 0.4038
Dl,co, % pred 47 (37–59) 42 (32–58) 0.1618
gOlD 1/2/3/4, % 5.7/33.1/44.5/16.7 5.5/27.3/50.9/16.4 0.8291
gOlD assessment a/B/C/D, % 3.7/22.5/4.9/69.0 5.5/16.4/7.3/70.9 0.6515
$2 exacerbations/year (%) 102 (41.6) 28 (50.9) 0.2096
Vitamin D, µg/la 18.1 (12.4–24.8) 16.2 (12.4–21.2) 0.2057
Vitamin D #20 µg/l (%)a 112 (56.9) 30 (69.8) 0.1185
A fum Igg, mg/l 27.7 (13.9–44.4) 43.2 (27.0–66.0) ,0.0001
Modified Reiff score $2 (%) 74 (30.2) 25 (45.5) 0.0297
sputum PPM (%)b 94 (59.5) 30 (76.9) 0.0436
Notes: Data are presented as n (%), median (interquartile range) or %. aBased on 240 COPD patients after exclusion of subjects taking vitamin D supplements: 197 non-sensitized 
and 43 sensitized patients. bBased on 197 patients of whom sputum results were available: 158 non-sensitized and 39 sensitized patients. P-values ,0.05 are shown in bold.
Abbreviations: COPD, chronic obstructive pulmonary disease; A fum, Aspergillus fumigatus; BMI, body mass index; ICs, inhaled corticosteroids; FeV1, forced expiratory 
volume in 1 second; % pred, percentage predicted; Dl,co, diffusion capacity of the lung for carbon monoxide; gOlD, global Initiative for Chronic Obstructive lung Disease; 
PPM, potential pathogenic microorganisms.
Table 3 Ige against A fum extract and rasp f1 in a contingency table
rAsp f1 IgE
present
rAsp f1 IgE
absent
Row total
A fum extract 
IgE present
17 (7.5) 14 (4.7) 31 (10.3)
A fum extract 
IgE absent
19 (6.3) 250 (83.3) 269 (89.7)
Column total 36 (12.0) 264 (88.0) 300 (100)
Note: Data are presented as n (%).
Abbreviations: A fum, Aspergillus fumigatus; rasp f1, A fum recombinant f1.
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Discussion
This study shows that sensitization to A fum occurs more 
frequently in COPD patients compared to smoking con-
trols, particularly when rAsp f1 is taken into account. A 
fum IgG levels are also significantly higher in the COPD 
group. A fum-sensitized COPD patients are more often 
male, with more proteobacteria in previous cultures, and 
depict a higher risk for bronchiectasis if sensitized to 
rAsp f1 or rAsp f3. Despite considerably lower vitamin 
D levels in COPD patients compared to controls, we 
did not find any relation with sensitization to A fum or 
bronchiectasis.
In our cohort, 34.3% of COPD patients had increased 
levels of total IgE compared to 22% in the control group. 
The higher prevalence of increased total IgE (47.3%) 
reported in another COPD cohort7 may be explained by 
demographical differences, variable inclusion criteria 
and the use of a lower cutoff for positivity. In terms of 
sensitization to A fum, we found an 18.3% prevalence in 
COPD when taking crude extract and recombinant antigens 
into account. These results are in line with previously 
reported data of prevalence between 8.5% and 16%.6,7,33,34 
As these studies are lacking an appropriate control group, 
our data clearly establish that sensitization to A fum is 
more common in COPD. We are aware of the younger 
age in our control group, but a median age difference of 
only 5 years seems insufficient to explain the higher rate 
of sensitization in COPD. The lack of skin prick tests is a 
limitation of our study because of a potential discordance 
between in vitro tests and skin prick tests to diagnose A fum 
sensitization.35
Bafadhel et al6 showed an association between 
sensitization and lower FEV
1
 in COPD. Although our 
sample size was twice as large, we could not observe 
any relationship with FEV
1
, diffusion capacity, exacer-
bations or GOLD stages. A more pronounced male pre-
dominance in the sensitized group may seem surprising, but 
Table 5 A fum sensitization and bronchiectasis in COPD
Variables COPD 
patients (n)
Modified Reiff 
score $2 (%)
P-values
Ige A fum extract 31 12 (38.7) 0.4752
Ige A fum extract or 
rasp f1–f4 and rasp f6
55 25 (45.5) 0.0297
Ige A fum extract 
without recombinants
9 0 (0)
Ige rasp f1 36 18 (50) 0.0208
Ige rasp f3 20 12 (60) 0.0079
Notes: Data are presented as n and n (%). P-values ,0.05 are shown in bold.
Abbreviations: COPD, chronic obstructive pulmonary disease; A fum, Aspergillus 
fumigatus; rasp f1, A fum recombinant f1; rasp f2, A fum recombinant f2; rasp f3, A 
fum recombinant f3; rasp f4, A fum recombinant f4; rasp f6, A fum recombinant f6.
Figure 2 Potential pathogenic microorganisms present in sputum samples of COPD patients by A fum sensitization status.
Notes: Occurrence of different species in sputum cultures. *P,0.05.
Abbreviations: COPD, chronic obstructive pulmonary disease; A fum, Aspergillus fumigatus; MRSA, methicillin-resistant Staphylococcus aureus.
$FKURPREDFWHU[\ORVR[LGDQV
$FLQHWREDFWHUVSHFLHV&LWUREDFWHUVSHFLHV
(QWHUREDFWHUVSHFLHV
.OHEVLHOODVSHFLHV
0RUD[HOODFDWDUUKDOLV
1HLVVHULDPHQLQJLWLGLV3DVWHXUHOODPXOWRFLGD
3URWHXVVSHFLHV3URYLGHQFLDUHWWJHUL
3VHXGRPRQDVDHUXJLQRVD
6HUUDWLDPDUFHVFHQV
6WDSK\ORFRFFXVDXUHXV
6WHQRWURSKRPRQDVPDOWRSKLOLD
6WUHSWRFRFFXVSQHXPRQLD
     


 &23'SDWLHQWV
056$
(VFKHULFKLDFROL
+DHPRSKLOXVLQIOXHQ]DH
&RPDPRQDVDFLGRYRUDQV
1RQVHQVLWL]HG6HQVLWL]HG
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2635
Aspergillus fumigatus sensitization and bronchiectasis in COPD
has been described before.36,37 Cigarette smoke exposure is 
known to facilitate development of sensitization, however 
we found no difference in pack-years and current smoking 
between A fum sensitized and non-sensitized COPD patients. 
This is in contrast to a recent paper about bidi smokers 
where current smoking seemed a risk factor for A fum sen-
sitization, irrespective of the presence of COPD.34 Despite 
similar disease severity, bronchiectasis was significantly 
more frequent in sensitized patients, particularly when 
sensitized to rAsp f1 or rAsp f3 (50% or 60% prevalence, 
respectively). Moreover, multivariate analysis showed that 
the associated risk for bronchiectasis was independent of 
gender, age, BMI, diffusion capacity, frequent exacerba-
tions and presence of PPM. Together, these observations 
support the hypothesis that A fum hypersensitivity might 
contribute to the development of bronchiectasis in COPD. 
Based on our results, we are not able to attribute causality. 
Furthermore, we realize that the association exists in two 
directions since the presence of bronchiectasis and COPD 
is a risk factor for colonization with A fum due to reduced 
mucociliary clearance and therapy with (inhaled) corticos-
teroids, antibiotics, etc. Nevertheless, some previous papers 
also suggested A fum as a causal factor for bronchiectasis. 
Clinically, colonization by A fum was associated with 
severity of bronchiectasis38 and development of bronchi-
olitis obliterans syndrome after lung transplantation.39 
Furthermore, A fum sensitization was associated with bron-
chiectasis, irrespective of ABPA in asthma40 and total IgE, 
which may represent an indirect marker of sensitization, 
seemed a risk factor for bronchiectasis in COPD patients.41 
From a mechanistic perspective, Aspergillus proteases play 
an important role. The serine protease activity of A fum 
stimulates MUC5AC, resulting in more mucus production 
by epithelial cells,42 and A fum allergen proteases Asp f3 
and Asp f15 have been shown to be responsible for the 
stimulation of the Th2 pathway and airway remodeling in 
a murine model.43
We could not measure blood eosinophils on the fro-
zen blood samples, and therefore, we could not fulfill 
criteria for ABPA in this cohort.44 In a recent paper, 
A fum IgG .27 mg/L was used in a cohort of sensitized 
asthma patients to distinguish patients having ABPA from 
patients without ABPA.45 This cutoff seems inappropriate 
in our A fum-sensitized COPD patients because the median 
A fum IgG value in our sensitized group was 43.2 mg/L. This 
could be explained by the fact that specific IgG is dependent 
on region, exposure and underlying disease. The higher 
levels of A fum-specific IgG, as a measure of exposure, may 
be due to reduced mucociliary function and reduced A fum 
clearance by innate immune cells in COPD patients versus 
controls.46 This reduced clearance of fungal allergens may 
facilitate sensitization.
Next to the higher prevalence of bronchiectasis, more 
A fum-sensitized COPD patients had P. aeruginosa and 
S. marcescens present in their sputum compared to A fum-non-
sensitized COPD patients. This finding further emphasizes 
the clinical relevance of our results since these pathogens 
may play a role in exacerbations and can become multidrug 
resistant. We did not report on culture results of A fum 
because the specific growth medium (Sabouraud) was only 
used on clinical indication. Moreover, sensitivity of culture 
for A fum is low and other detection methods such as poly-
merase chain reaction (PCR) may better reflect the presence 
of A fum in the airways.47 Further prospective studies are 
therefore needed to explore the relationship between A fum 
colonization, sensitization and bronchiectasis. In line with 
these unknowns is the potential role of A fum on vitamin D 
receptor downregulation20 as well as the effect of vitamin D 
deficiency on A fum sensitization19,21 and disease severity 
in bronchiectasis.22 Our results did not show any obvious 
Table 6 Association of bronchiectasis (modified Reiff score $2) and sensitization to rasp f1 or rasp f3 in COPD by a logistic 
regression model
Variables In all COPD patients (n=300) In COPD patients with sputum 
samples (n=197)
OR (95% CI) P-values OR (95% CI) P-values
sensitization to rasp f1 or rasp f3 2.8 (1.42–5.53) 0.0030 3.4 (1.56–7.48) 0.0021
gender 1.5 (0.81–2.75) 0.1953 1.8 (0.82–4.04) 0.1424
age 1.0 (1.00–1.07) 0.0349 1.03 (0.99–1.07) 0.2064
BMI 1.0 (0.91–1.01) 0.1198 0.96 (0.89–1.03) 0.2155
Dl,co, % pred 1.0 (0.97–1.00) 0.1353 0.98 (0.96–1.01) 0.1572
$2 exacerbations/year 1.6 (0.97–2.72) 0.0642 2.11 (1.13–3.94) 0.0188
PPM in sputum na 0.68 (0.35–1.32) 0.2573
Note: P-values ,0.05 are shown in bold.
Abbreviations: COPD, chronic obstructive pulmonary disease; rasp f1, A fum recombinant f1; rasp f3, A fum recombinant f3; OR, odds ratio; CI, confidence interval; BMI, 
body mass index; Dl,co, diffusion capacity of the lung for carbon monoxide; % pred, percentage predicted; PPM, potential pathogenic microorganisms; na, not applicable.
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relationship, but it is clear that we cannot rule out a role of 
vitamin D deficiency based on this cross-sectional analysis 
with a relatively small sample size.
We are the first to report data on IgE against recombinant 
A fum allergens in COPD. rAsp f1 is a major and species-
specific allergen of A fum, which in contrast to A fum extract 
shows no cross-reactivity with proteins of other species.8 
Exposure to rAsp f1 only occurs during fungal growth, which 
makes rAsp f1 a reliable and relevant antigen.48 Although 
testing with the crude extract is assumed to be more sensi-
tive than testing with the recombinants, we showed a higher 
prevalence of sensitization to rAsp f1 compared to the crude 
extract. This finding questions the reliability of the crude 
extract to diagnose A fum sensitization and emphasizes its 
known limitations such as cross-reactivity, lability and lack of 
standardization. However, it remains unclear why sensitiza-
tion to rAsp f2 and rAsp f3 (other major allergens of A fum) 
was less frequently detected. Several reasons could explain 
why bronchiectasis was not present in the patients only sen-
sitized against the crude A fum extract. The nine patients only 
sensitized to the crude A fum extract may be false positive 
due to cross-reactivity. On the other hand, specific allergens 
may be required to trigger pathways that contribute to bron-
chiectasis development, although controversial in ABPA.10,49 
The role of different A fum allergens in the pathogenesis of 
ABPA and bronchiectasis is far from understood, and .25 
distinct A fum allergens have been identified.
The prevalence of bronchiectasis in our cohort (33%) 
lies within the wide range reported in other studies 
(4%–60%).15,50,51 Although there is no specific radiologic scor-
ing system validated for bronchiectasis in COPD, the modi-
fied Reiff score, which we applied, has been used in several 
studies.29,52,53 Nevertheless, overestimation of bronchiectasis 
in COPD is possible since limited bronchiectasis is seen on 
high-resolution CT scans of healthy individuals and is also 
related to lung aging.30,54 We tried to avoid overestimation 
by considering only a modified Reiff score of $2 as mean-
ingful and showed that the prevalence of bronchiectasis was 
at least higher in our patient cohort than in the controls.
Conclusion
The results show a high prevalence of A fum sensitization 
in COPD patients and highlight a potential role of rAsp f1 
and rAsp f3 in COPD-related bronchiectasis. Because of the 
retrospective, observational design of this study, we were 
not able to demonstrate a causal relationship. Nevertheless, 
this is the first report about the association between A fum 
sensitization, including five recombinant antigens, and 
bronchiectasis in COPD. An association between A fum 
sensitization and vitamin D deficiency was not found. The 
search for underlying mechanisms in the development of 
bronchiectasis in COPD is relevant, since the presence of 
bronchiectasis in COPD influences management and prog-
nosis of the disease. Prospective, longitudinal studies are 
needed to prove causality and to allow speculation about 
preventive interventions.
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